How does abatacept really work in rheumatoid arthritis?
Curr Opin Rheumatol
; 30(3): 295-300, 2018 05.
Article
em En
| MEDLINE
| ID: mdl-29401118
ABSTRACT
PURPOSE OF REVIEW The purpose of this review is to summarize the current knowledge concerning the mechanisms of action of Abatacept in patients with rheumatoid arthritis. RECENT FINDINGS:
Abatacept (CTLA-4Ig) represents a soluble, recombinant, fully humanized fusion protein, comprising the extracellular domain of CTLA-4 and the Fc portion of IgG1. Abatacept binds to the costimulatory molecules CD80 and CD86 on antigen-presenting cells (APC), thereby blocking interaction with CD28 on T cells. In humans, Abatacept treatment was shown to be effective in patients with various autoinflammatory diseases including rheumatoid arthritis. Although the prevention of T-cell activation by interfering with signaling via CD28 still represents the main mechanism of action Abatacept acts on additional cell populations including regulatory T cells (Treg), monocytes/macrophages, osteoclasts, and B cells.SUMMARY:
Effects of Abatacept on other cell populations besides T cells have to be taken into account and might represent a valuable contribution to the therapeutic success.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Artrite Reumatoide
/
Leucócitos Mononucleares
/
Antirreumáticos
/
Abatacepte
/
Macrófagos
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article